HPV (human papilloma virus) predicts cervical radiotherapy efficacy:
This article was originally published in Clinica
Executive Summary
Testing for the human papilloma virus (HPV) in women with advanced cervical cancer could help predict how well the patients will respond to radiotherapy used to cure the disease, according to a Swiss study. Dr Katja Lindel and colleagues from the University Berne Hospital report that HPV is an independent prognostic parameter for clinical outcome and a predictive factor for radiation response. Results from their study of 40 patients treated with radiotherapy showed that HPV-positive women had slightly higher rates of overall survival and were significantly more likely to have their cancer go into remission than HPV-negative women, 67% versus 33%, respectively.